Selecting a Contract Development and Manufacturing Organisation for High-Potency Active Pharmaceutical Ingredient small molecule programmes requires a structured, evidence-based evaluation. The critical criteria are: validated Occupational Exposure Band 5 containment, Good Manufacturing Practice certification that explicitly covers the high-potency suite, a co-located and Good Manufacturing Practice-approved analytical laboratory, demonstrated experience with the relevant dosage forms and a verifiable track record in potent compound development. This guide sets out each of those criteria in sequence to support pharmaceutical and biotechnology development leaders in making a rigorous sourcing decision.
What “Integrated” Means in an HPAPI Development Context
An integrated Contract Development and Manufacturing Organisation for High-Potency Active Pharmaceutical Ingredient small molecule programmes is one that combines formulation development, analytical testing and Good Manufacturing Practice-compliant manufacturing within a single operational and quality framework. For high-potency compounds, that integration carries particular weight. Every handling event involving a potent material represents a potential exposure risk. Consolidating development activities under one roof, within purpose-built containment infrastructure, reduces the number of those events and removes the need for inter-site material transfers during early development. It is important to distinguish between a Contract Development and Manufacturing Organisation that has retrofitted containment provisions to a general-purpose facility and one that has constructed a dedicated high-potency suite from the outset, with engineering controls, monitoring systems and standard operating procedures designed specifically around high-potency operations.
Step 1: Confirm Occupational Exposure Band Classification and Containment Capability
The most immediate selection criterion for High-Potency Active Pharmaceutical Ingredient small molecule programmes is whether the Contract Development and Manufacturing Organisation can safely handle the compound in question. This is determined by the compound’s Occupational Exposure Band classification and the corresponding Occupational Exposure Limit.
Understanding the Occupational Exposure Band Classification System
Occupational Exposure Bands are a five-tier classification system used across the pharmaceutical industry to categorise compounds according to their potency and associated health risk. Occupational Exposure Band 1 represents the least toxic substances and Occupational Exposure Band 5 represents the most potent and potentially hazardous. Each band corresponds to a defined Occupational Exposure Limit range, expressed in micrograms per cubic metre of air. A Contract Development and Manufacturing Organisation must demonstrate that its engineering controls reliably contain the compound within the limits required by the applicable band.
For oncology actives, hormonal compounds and other highly potent small molecules, Occupational Exposure Band 5 capability is frequently required. Sponsors should request formal, documented evidence that the Contract Development and Manufacturing Organisation’s containment infrastructure is validated to the specific Occupational Exposure Limit threshold applicable to the programme, not simply that the facility is described
as capable in general terms.
Questions to Raise With a Prospective CDMO Regarding Containment
- What is the lowest Occupational Exposure Limit your facility is validated to handle, expressed in micrograms per cubic metre of air?
- How is containment performance monitored and evidenced?
- Is the high-potency suite operated under a dedicated quality management framework?
- Has the High-Potency Active Pharmaceutical Ingredient-specific area been subject to regulatory inspection and approval?
Adragos Pharma’s Occupational Exposure Band 5 Containment Capability
Athens Facility – Purpose-Built in 2023
Adragos Pharma’s dedicated High-Potency Active Pharmaceutical Ingredient laboratory at its Athens facility handles compounds up to Occupational Exposure Band 5, with an Occupational Exposure Limit no lower than 0.5 μg/m³. The laboratory was built in 2023 in direct response to the growing demand for High-Potency Active Pharmaceutical Ingredient new product development, particularly for oncology medicines. It was certified as European Union Good Manufacturing Practice compliant by the Greek Regulatory Authorities in 2023 and is staffed by experienced specialist personnel.
Learn more about Adragos’ High-Potency Active Pharmaceutical Ingredient capability at the Athens facility.
Step 2: Verify Good Manufacturing Practice Certification That Covers the High-Potency Suite Specifically
European Union Good Manufacturing Practice certification is a baseline requirement for any Contract Development and Manufacturing Organisation involved in pharmaceutical development. For High-Potency Active Pharmaceutical Ingredient programmes, the essential question is whether that certification explicitly covers the high-potency manufacturing and testing areas, rather than only the general facility.
What to Request From a CDMO’s Quality Documentation
A Contract Development and Manufacturing Organisation’s site master file and manufacturing authorisation must accurately reflect the High-Potency Active Pharmaceutical Ingredient activities conducted on-site. Sponsors should request the Good Manufacturing Practice certificate and confirm that the high-potency suite is named within it. They should also ask for the date and outcome of the most recent regulatory inspection covering those areas. The European Medicines Agency’s Good Manufacturing Practice guidelines define the standards against which High-Potency Active Pharmaceutical Ingredient facilities operating within the European Union are assessed and certified.
Adragos’ European Union Good Manufacturing Practice Certified HPAPI Suite
Greek Regulatory Authority Certification – 2023
Adragos’ Athens High-Potency Active Pharmaceutical Ingredient laboratory received European Union Good Manufacturing Practice certification from the Greek Regulatory Authorities in 2023. That certification covers lab-scale manufacturing operations and analytical testing for both solid and liquid pharmaceutical products containing high-potency actives.
Step 3: Assess Analytical Capability and Co-location
For High-Potency Active Pharmaceutical Ingredient programmes, analytical testing must be conducted within or directly integrated with the containment environment. Transporting potent materials to an external or general-purpose analytical laboratory introduces additional handling events and exposure risk, and complicates the chain-of-custody documentation required under Good Manufacturing Practice.
Key Evaluation Criteria for an HPAPI Analytical Laboratory
- Whether the analytical laboratory is physically co-located with thehigh-potency manufacturing suite
- Whether the laboratory holds its own Good Manufacturing Practiceapproval, distinct from any general facility certification
- Whether the laboratory is configured to test both active substancesand finished drug products in the dosage forms relevant to the programme
- Whether analytical method development and method validation can beperformed in-house, reducing dependence on external contractlaboratories
Co-located analytical capability is of particular value during formulation development, where iterative testing of prototype formulations must proceed without logistical delay or unnecessary material transfers.
Analytical Infrastructure at the Adragos Athens Facility
GMP-Approved Laboratory Within the HPAPI Containment Environment
Adragos’ Athens High-Potency Active Pharmaceutical Ingredient facility includes a dedicated European Union Good Manufacturing Practice approved analytical laboratory equipped to test both liquid and solid
pharmaceutical products and active substances, within the same containment environment as the manufacturing suite.
Step 4: Confirm Dosage Form Scope and Manufacturing Experience
High-potency small molecules are developed across a range of dosage forms. The manufacturing capability of a prospective Contract Development and Manufacturing Organisation must correspond to the intended product format.
Questions to Ask Regarding Manufacturing Scope
- Which dosage forms has the Contract Development and Manufacturing Organisation manufactured under validated High-Potency Active Pharmaceutical Ingredient containment conditions?
- Is the manufacturing area configured and validated for the specific product type under development?
- What scale of production is supported, from early research and development through to the stages required for the programme?
Dosage Form Capability at Adragos Athens
Adragos’ Athens laboratory supports lab-scale manufacturing for research and development production of both solid and liquid pharmaceutical products containing high-potency actives.
Step 5: Evaluate Experience and Track Record in HPAPI Development
Technical infrastructure alone does not determine a Contract Development and Manufacturing Organisation’s suitability for complex High-Potency Active Pharmaceutical Ingredient programmes. The depth of experience held by the development team is equally important. Sponsors should seek evidence of prior programmes, including the compound classes handled, the development stages supported and the regulatory frameworks within which work was conducted.
Why Development Track Record Matters in HPAPI Programmes
A Contract Development and Manufacturing Organisation that has established a dedicated High-Potency Active Pharmaceutical Ingredient programme, recruited specialist personnel and built its laboratory infrastructure in response to genuine market demand presents a materially lower execution risk than one entering this space for the first time. Adragos is an experienced developer of value-added medicines with a
proven track record in High-Potency Active Pharmaceutical Ingredient development programmes.
